Navigation Links
Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:10/2/2009

Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast today, October 2, 2009 at 6:30 a.m. MT (8:30 a.m. ET) to update investors on the Phase 3 program for REOLYSIN. To access the conference call by telephone, dial 1-416-644-3426 or 1-800-732-1073. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2828320 or through the Company's website at www.oncolyticsbiotech.com. Please connect at least 15 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com and will also be available by telephone through October 9, 2009. To access the telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation number 4169017 followed by the number sign.

About the Special Protocol Assessment Process

Upon the request of a study sponsor, the FDA will evaluate certain protocols and issues relating to the protocols to assess whether they are adequate to meet scientific and regulatory requirements; this includes clinical protocols for Phase 3 trials whose data will form the primary basis for an efficacy claim that will be part of an original Biologics License Application. For more information about the SPA process, please go to:

http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf

About REOLYSIN

REOLYSIN is a proprietary formulation of the human reovirus that acts primarily as a direct cytotoxic agent. Reovirus is naturally occurring (not genetically engineered) and has been
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company focused on the development of autologous cell ... Phase 1/2 clinical trial of RCT-01, being tested ... has been enrolled and their tissue biopsy sent ... is comprised of non-bulbar dermal sheath (NBDS) cells ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... 14. She has accepted the position of vice president of instruction at Chippewa ... , “I greatly appreciated the opportunity to lead SIUE during the past ...
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , ... an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative ... of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, ...
(Date:6/29/2015)... 2015   Pharnext SAS today announced that data ... treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented in ... Nerve Society (PNS) Biennial Meeting at the Quebec Congress Center ... - July 2, 2015. At Poster Viewing Session ... 5p.m. to 7p.m. EDT: Poster 23: "A ...
Breaking Biology Technology:RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2
... PharmAthene, Inc.,(Amex: PIP ) a biodefense ... announced that the Delaware Chancery Court,today issued a ... dismiss,PharmAthene,s complaint, which alleges that it has a ... SIGA,s drug candidate, SIGA-246. SIGA,s,request to dismiss the ...
... Helix BioPharma Corp.,(TSX: HBP/Frankfurt: WKN 918846) announced today ... Inc. ("KBI") to develop a process for,preparing L-DOS47 ... clinical testing., "This new arrangement advances the ... with L-DOS47," said John Docherty, Helix,s,president. "The lyophilized ...
... Bristol-Myers Squibb,Company (NYSE: BMY ) will announce ... on Thursday, January 31. During a 10 a.m. (ET) ... information and will,address inquiries from investors and analysts., ... to a live,webcast of the call at http://www.bms.com/ir ...
Cached Biology Technology:Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthene's Legal Action in Breach of Contract Lawsuit Against SIGA 2Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format 2Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format 3
(Date:6/10/2015)... June 10, 2015 According ... Market by Technology (Ultrasound, TOF, Structured Light, Stereo ... Entertainment, Automotive) and by Geography - Trends & ... the market is expected to reach $3,319.71 Million ... between 2015 and 2020. Browse 71 ...
(Date:6/9/2015)... DUBLIN , June 09, 2015 ... the addition of the "Gesture Recognition & ... Application (Consumer Electronics, Automotive, & Others), Product (Biometric ... Forecast to 2020" report to their offering. ... sensing market is expected to reach $ 23.55 ...
(Date:6/8/2015)... 2015  The Secure Identity & Biometrics ... Troy Potter of L-3 National Security ... a non-profit association that was established in February ... implementation of solutions that protect and secure identity ... Photo - ...
Breaking Biology News(10 mins):3D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... Researchers at Washington University in St. Louis have figured ... complex to its neighboring membrane in a photosynthetic bacterium, ... in photosynthesis. Robert Blankenship, Ph.D., Markey Distinguished Professor ... a team that for the first time combined chemical ...
... -- Three leading research centers based in Woods Hole, ... a new alliance that will bring their combined scientific ... facing society today and spawn scientific growth and job ... consortium comprises the Woods Hole Marine Biological Laboratory (MBL), ...
... that appears to prevent some men from conceiving children ... according to University of Iowa researchers reporting their findings ... American Journal of Human Genetics . Although female ... have proven very effective for family planning, no similar ...
Cached Biology News:Orientation of antenna protein in photosynthetic bacteria described 2Orientation of antenna protein in photosynthetic bacteria described 33 Woods Hole scientific institutions forge alliance to address societal issues 23 Woods Hole scientific institutions forge alliance to address societal issues 3Gene discovery could lead to male contraceptive 2
Request Info...
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
... provides the premium quality siRNAs you need ... can be readily ordered online by providing ... by providing the sense and antisense siRNA ... Validated and Silencer Pre-designed ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer ...
Biology Products: